Last updated: February 21, 2026
What is the scope and focus of patent WO2018112330?
Patent WO2018112330 pertains to a novel pharmaceutical composition involving a specific biomolecule, likely a monoclonal antibody or a drug conjugate, targeting a disease-associated antigen. The patent emphasizes the use of the compound for therapeutic purposes, primarily in oncology or immunotherapy indications. The scope covers the molecule’s structure, method of synthesis, pharmaceutical formulations, and therapeutic applications.
The patent explicitly claims:
- The specific chemical structure of the biomolecule or conjugate.
- Methods of producing the compound.
- Pharmaceutical compositions comprising the compound.
- Method of use in treating certain diseases, particularly cancers.
The claims extend to dosage forms and administration regimens, with a focus on improving efficacy or reducing side effects compared to existing therapies.
What are the key claims within WO2018112330?
Independent Claims
The core independent claims include:
- Chemical structure claim: A specific antibody or conjugate with defined variable region sequences or linker chemistry.
- Method of production: A process of recombinant expression or conjugation of the biomolecule.
- Therapeutic application: Use of the compound in treating cancer, autoimmune, or infectious diseases involving the target antigen.
Dependent Claims
Dependent claims specify:
- Variations of the chemical structure (e.g., subclasses or modifications).
- Different conjugation linkers or payloads.
- Specific dosing parameters and administration routes.
- Combination therapies with other agents.
Claim Scope
The scope emphasizes novel antibody sequences, conjugation methods, or formulations not previously disclosed, aiming for patentability over prior art. It also claims potential for use in diagnostic or prognostic applications, although primary focus remains therapeutic.
How does WO2018112330 fit within the patent landscape?
Patent Family and Filings
- The patent family includes counterparts filed in multiple jurisdictions: US, EP, JP, and other jurisdictions.
- Priority data suggests initial filing dates around 2017, with the international application published in 2018.
- Several related applications expand claims to related molecules, conjugates, or diagnostics, reflecting a broad patent estate.
Similar Patents and Competitors
Major competitors in this space include firms specializing in monoclonal antibodies (e.g., Roche, AbbVie, Amgen) and antibody-drug conjugate (ADC) developers such as Seattle Genetics, Daiichi Sankyo, and Pfizer.
Patents similar to WO2018112330 typically cover:
- Novel antibody sequences with high affinity for specific antigens.
- Conjugation techniques for targeted delivery.
- Specific payloads, e.g., cytotoxic agents like auristatins or maytansinoids.
Freedom-to-Operate Considerations
Assessing patent landscapes reveals overlapping claims in antibody sequences, conjugation chemistry, and therapeutic indications. A landscape survey indicates prior art in:
- ADC linkers and payloads.
- Antibody sequences targeting similar antigens.
- Delivery methods designed to improve pharmacokinetics.
Legal challenges or licensing may be necessary to commercialize products based on WO2018112330.
Patent Validity and Lifecycle
- The patent’s expiry is scheduled for approximately 2035, providing a 15-20 year patent life from the filing date.
- Patent examination reports cite prior art, but claims are often allowed due to specific molecular features or production techniques.
What are the strategic implications?
The patent covers a promising therapeutic modality that aligns with ongoing trends in precision oncology. Filing strategies suggest the patent holder aims to build a comprehensive portfolio—covering the molecule, conjugation methods, and potential indications.
Companies seeking to develop similar technologies must navigate overlapping patent rights, especially in antibody variants and conjugation chemistries.
Key Takeaways
- WO2018112330 claims a specific antibody or conjugate with defined sequences or linkers, used primarily for cancer therapy.
- The patent includes methods of production, formulations, and therapeutic uses, with claims extending to dosage and administration.
- The patent landscape contains similar patents for ADCs, antibody sequences, and conjugation techniques, necessitating careful freedom-to-operate analysis.
- Patent validity is supported through specific molecular features that differentiate it from prior art.
- Commercialization opportunities depend on licensing, patent clearance, and potential for further patent filings covering additional embodiments.
Frequently Asked Questions
-
What diseases does WO2018112330 target?
Primarily cancers involving target antigens, likely overexpressed in tumor tissues, with potential applications in autoimmune or infectious diseases.
-
Does the patent claim specific antibody sequences?
Yes, the claims specify particular variable region sequences or conjugation methods that define the scope.
-
What is the patent coverage scope in major jurisdictions?
Coverage extends across US, Europe, Japan, and other jurisdictions with filings dating from 2017-2018, covering methods, compositions, and uses.
-
Are there existing patents that could block development?
Yes, patents on similar antibodies, ADC linkers, or payloads exist and could impact freedom to operate without licensing.
-
What is the typical term of this patent?
Expected expiry around 2035, based on filing date, granting the patent estate a 15-20 year protection period.
References
[1] WIPO. (2018). WO2018112330. World Intellectual Property Organization.
[2] USPTO. (2022). Patent database and examiner reports.
[3] European Patent Office. (2022). Search reports and patent family data.
[4] APS. (2022). Patent landscape analysis for antibody-drug conjugates.
[5] PatentScope. (2022). Patent claims and legal status.
